International Journal on Science and Technology (IJSAT)

E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

A Survey on Computer Vision in Pharmaceutical Therapy

BH D D Priyanka [1], Dr .k. Selva Kumar [2], Dr. Karuna Arava [3]

[1] Research Scholar, [2] Professor, [3] Research Co-Supervisor
[1,2,3]Department of Information Technology, Annamalai University, Chidambaram Tamil Nadu, India

Abstract

The pharmaceutical industry is increasingly adopting computer vision technologies to enhance process accuracy, streamline operations, and maintain regulatory compliance. As production volumes grow and quality standards tighten, traditional manual methods struggle to meet industry demands. This paper reviews the role of computer vision—particularly models like YOLO11 in automating critical pharmaceutical tasks such as pill identification, packaging inspection, inventory tracking, and pharmacy workflow optimization. By enabling real-time visual recognition and analysis, computer vision systems improve product quality control, reduce inventory errors, and support efficient retail pharmacy operations. The integration of vision-based AI into pharmaceutical environments is helping manufacturers, distributors, and pharmacies achieve greater consistency, safety, and operational excellence.

Keywords: Computer vision, Pharmaceutical industry, Object detection, Quality control, Inventory management; Packaging inspection, YOLO11, Automation.

1. INTRODUCTION

The integration of computer vision into pharmaceutical therapy represents a transformative shift in how medication-related processes are conducted, monitored, and optimized. Traditionally, pharmaceutical therapy has depended on manual protocols and established pharmacological methods for drug development, quality assurance, and patient care. With the advancement of artificial intelligence (AI), particularly in the area of computer vision, the industry is now witnessing improved precision and efficiency across various stages of pharmaceutical workflows.

Computer vision, which enables machines to interpret and analyze visual data, is being increasingly applied in pharmaceutical environments for tasks such as pill identification, packaging verification, inventory monitoring, and medication adherence tracking. These applications not only help maintain high standards of product quality but also ensure compliance with regulatory requirements and streamline operations within manufacturing units, pharmacies, and healthcare facilities.

This paper provides a structured overview of how computer vision is currently used in pharmaceutical therapy. It highlights relevant literature, examines its role in automating critical processes, and addresses practical challenges encountered in real-world settings. By focusing on current implementations, this review underscores how computer vision is contributing to safer, more accurate, and more efficient pharmaceutical practices.

2. LITERATURE SURVEY

Investigated the role of artificial intelligence in healthcare with a focus on how clinicians perceive and trust AI during decision-making. The study emphasized system transparency, explainability, and ethical design. It concluded that while clinicians are willing to adopt AI, trust is weakened by opaque models and ambiguous accountability. Future development should prioritize user-centered design and real-world validation [1].

Proposed the CONSORT-AI extension to clinical trial reporting guidelines, aiming to improve transparency and reproducibility for AI interventions. It mandates reporting on algorithm versioning, dataset quality, and human-AI interaction. However, as a voluntary standard, its adoption remains limited, necessitating journal-level enforcement and regulatory encouragement [2].

Applied RGB-D camera systems for daily activity recognition, combining color and depth data for accurate human motion interpretation. Effective in elderly care scenarios, its performance declined under occlusions and poor lighting. Future work may include sensor fusion and adaptive lighting correction for robustness [3].

Introduced Residual Networks (ResNet), a deep architecture that solved the vanishing gradient issue through skip connections. It allowed training of very deep models and significantly improved image recognition accuracy. While highly effective, its static architecture could benefit from future dynamic residual designs [4].

Developed Long-term Recurrent Convolutional Networks (LRCN), integrating CNNs and LSTMs for video-based recognition tasks. It performed well on sequential data like activity recognition but struggled with long-term temporal dependencies. Enhancements with transformers may provide better performance [5].

Demonstrated that deep neural networks can be easily fooled by adversarial images, which appear nonsensical to humans but receive high-confidence predictions from AI. This exposed vulnerabilities in current models, urging the development of adversarial defenses and human-in-the-loop systems [6].

Presented the R-CNN model for object detection, combining selective region proposals with deep feature extraction for high accuracy. While it marked a leap forward, its slow performance led to successors like Fast and Faster R-CNN, which aimed to balance speed and precision [7].

Proposed AlexNet, a deep CNN that popularized ReLU activations, dropout, and GPU training. It set new standards for image classification and catalyzed the deep learning era, though later models addressed its limitations in scalability and energy efficiency [8].

Reviewed object detection models like YOLO, SSD, and R-CNN variants, comparing their accuracy and efficiency. It identified issues with detecting small or overlapping objects and recommended hybrid approaches to improve detection in complex scenes [9].

Highlighted YOLO's one-stage detection capability that enables real-time processing with decent accuracy, particularly useful for surveillance and robotics. Its coarse grid struggles with smaller objects, suggesting that future models should include better multi-scale feature extraction [10].

Expanded upon YOLO applications in smart environments, noting the efficiency of YOLOv3 and YOLOv4 in time-sensitive use cases. However, precision dropped in detailed scenes, indicating a need for deeper contextual integration, possibly through segmentation models [11].

Improved YOLOv3 by optimizing anchor boxes and enhancing multi-scale detection. These upgrades improved accuracy for small and varied objects but increased computational demands, which future versions could reduce using pruning or transformers [12].

Employed semi-supervised learning in Faster R-CNN for person detection in video surveillance with limited labeled data. While accurate, real-time deployment remains constrained by processing requirements. Edge-based implementations could overcome this hurdle [13].

Reviewed object detection applications in domains like agriculture, manufacturing, and smart cities. It emphasized algorithm suitability and suggested incorporating explainable AI to increase transparency and user trust in practical use cases [14].

Summarized early computer vision applications in food quality inspection, focusing on grading, defect detection, and automation. Environmental sensitivity was a challenge, and future methods may use AI to enable adaptive inspections based on varying conditions [15].

3. APPLICATIONS OF COMPUTER VISION IN PHARMACEUTIAL THERAPY

3.1 Automated Inspection for Product Quality

Computer vision technologies enable rapid and precise inspection of pharmaceutical products during manufacturing. These systems analyse pills and capsules to detect defects such as surface cracks, discoloration, and incorrect labelling. By automating this quality control step, manufacturers can ensure that only products meeting strict safety and regulatory standards proceed further, minimizing the risk of faulty medications reaching consumers.

3.2 Real-Time Inventory Monitoring and Counting

AI-powered computer vision systems provide efficient tracking and counting of medications in storage or production lines. By using cameras and trained models, pharmacies and manufacturers can continuously monitor stock levels of pills and capsules with high accuracy. This automated approach helps reduce manual errors, streamlines supply chain management, and prevents problems like overstocking or medication shortages.

3.3 Customer Movement Analysis for Pharmacy Layout Optimization

Retail pharmacies can use computer vision to map how customers move within the store by creating heat maps of foot traffic. Understanding which areas receive the most attention—whether at prescription counters or medicine aisles—allows pharmacy managers to reorganize store layouts and optimize staffing. This leads to improved customer experience by reducing wait times and making the shopping process more efficient.

3.4 Automated Blister Pack Verification

Blister packaging plays a critical role in medication safety, but manual inspection can miss errors such as missing or misplaced pills. Computer vision systems can automatically scan blister packs to detect any absent or damaged pills and verify that seals and compartments are intact. This reduces the chance of dosage errors and helps maintain consistent product quality before distribution.

3.5 Monitoring and Assessment of Liquid Medication Bottles

Computer vision applications extend to monitoring liquid pharmaceuticals, such as saline or IV fluids. By analysing bottle images, these systems can determine fill levels and detect improperly sealed or damaged containers. This technology aids healthcare providers and pharmacies in managing liquid medication inventories more precisely, reducing waste and ensuring patient safety.

4. CHALLENGES IN INTEGRATING COMPUTE VISION IN PHARMACEUTICAL THERAPY

Despite the promising potential of computer vision in pharmaceutical therapy, there are several challenges that hinder its widespread implementation.

4.1 Data Quality and Availability

High-quality datasets are essential for training computer vision models. However, obtaining annotated medical images and patient data can be challenging due to privacy concerns, ethical considerations, and the need for large-scale, diverse datasets. Additionally, inconsistencies in imaging techniques across healthcare facilities may impact the generalization of CV models.

4.2 Regulatory and Ethical Concerns

The integration of computer vision into pharmaceutical therapy raises concerns regarding patient privacy, data security, and the ethical use of AI. Regulatory bodies, such as the FDA, must establish clear guidelines for the approval and use of CV-based healthcare solutions, ensuring they meet safety and efficacy standards.

4.3 Model Interpretability and Trust

Although deep learning models have demonstrated remarkable performance in medical imaging tasks, they are often perceived as “black boxes” due to their lack of interpretability. Ensuring that CV systems provide transparent and understandable results is critical for gaining the trust of healthcare providers and patients.

5. FUTURE DIRECTIONS

The future of computer vision in pharmaceutical therapy looks promising, with several exciting developments on the horizon:

1. **Integration with Artificial Intelligence:** The combination of computer vision and AI-powered predictive models will enable more accurate personalized therapies and real-time decision-making.
2. **Augmented Reality (AR) in Surgery and Drug Delivery:** AR systems, enhanced by computer vision, could assist in drug delivery during surgeries by precisely targeting affected areas, improving treatment accuracy.
3. **Collaboration Across Disciplines:** The collaboration between computer scientists, clinicians, and pharmaceutical researchers will accelerate the development of robust CV tools that can address complex healthcare challenges.

6. CONCLUSION

Computer vision is rapidly transforming pharmaceutical therapy, offering innovative solutions for drug discovery, patient monitoring, treatment personalization, and disease detection. While challenges exist, particularly in data quality, regulatory approval, and ethical considerations, the potential benefits of computer vision in healthcare are immense. As technology continues to evolve, computer vision is poised to play a pivotal role in shaping the future of pharmaceutical therapy and personalized healthcare. This survey paper has provided a comprehensive overview of the current state of computer vision in pharmaceutical therapy, highlighting the various applications and challenges while offering insights into future developments. The integration of CV into healthcare is an exciting and evolving area that promises to enhance the efficacy and accessibility of treatments for patients worldwide.

REFERENCES

1. Asan, O., Bayrak, A. E., & Choudhury, A. Artificial intelligence and human trust in healthcare: focus on clinicians. J. Med. Internet Res. 22, e15154 (2020).
2. Liu, X. et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension. BMJ 370, m3164 (2020).
3. Zhang, C. & Tian, Y. RGB-D camera-based daily living activity recognition. J. Comput. Vis. Image Process. 2, 12 (2012).
4. K. He, X. Zhang, S. Ren, and J. Sun, “Deep residual learning for image recognition,” in The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), June 2016.
5. J. Donahue, L. Anne Hendricks, S. Guadarrama, M. Rohrbach, S. Venugopalan, K. Saenko, and T. Darrell, “Long-term recurrent convolutional networks for visual recognition and description,” in The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), June 2015.

6. A.Nguyen, J. Yosinski, and J. Clune, “Deep neural networks are easily fooled: High confidence predictions for unrecognizable images,” in The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), June 2015.
7. R. Girshick, J. Donahue, T. Darrell, and J. Malik, “Rich feature hierarchies for accurate object detection and semantic segmentation,” in The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), June 2014.
8. A.Krizhevsky, I. Sutskever, and G. E. Hinton, “Imagenet classification with deep convolutional neural networks,” in Advances in Neural Information Processing Systems 25,F. Pereira, C. J. C. Burges, L. Bottou, and K.Q.Weinberger, Eds.Curran Associates, Inc., 2012, pp. 1097–1105.
9. W. Zhiqiang, L. Jun, A review of object detection based on convolutional neural network, in: 2017 36th Chinese Control Conference (CCC), 2017, pp. 11104–11109. doi: 10.23919/ChiCC.2017.8029130
10. Arya MC, Rawat A. A review on YOLO (You Look Only One)–an algorithm for real time object detection. J Eng Sci. 2020;11:554-7.
11. Arya, Mukesh Chandra, and Anchal Rawat. "A review on YOLO (You Look Only One)–an algorithm for real time object detection." J Eng Sci 11 (2020): 554-7.
12. Ju, M.; Luo, H.; Wang, Z.; Hui, B.; Chang, Z. The Application of Improved YOLO V3 in Multi-Scale Target Detection. Appl. Sci. 2019, 9, 3775.
13. Wei H, Kehtarnavaz N (2019) Semi-supervised faster RCNN-based person detection and load classification for far field video surveillance. Mach Learn Knowl Extraction 1(3):756–767.
14. Chavan C., Hembade S., Jadhav G., Komalwad P., Rawat P. Computer vision application analysis based on object detection.
15. Brosnan T, Sun D-W. "Improving quality inspection of food products by computer vision –a review." Journal of Food Engineering, 2004, 61(1): 3–16.